past
two
decad
seen
emerg
spread
novel
viral
respiratori
tract
pathogen
human
sever
acut
respiratori
syndrom
coronaviru
sarscov
avian
strain
influenza
viru
swine
influenza
middl
east
respiratori
syndrom
coronaviru
merscov
specif
treatment
option
avail
carri
high
morbid
mortal
rate
merscov
first
report
jeddah
septemb
isol
saudi
patient
die
sever
respiratori
ill
multiorgan
failur
sinc
commun
hospit
acquir
mer
case
report
twentynin
countri
middl
east
africa
europ
north
america
asia
three
year
sinc
first
discoveri
mani
fundament
question
regard
epidemiolog
pathogenesi
immun
respons
optim
treatment
regimen
merscov
remain
unansw
merscov
continu
global
concern
illustr
recent
nosocomi
outbreak
nation
guard
hospit
riyadh
saudi
arabia
hospit
seoul
republ
korea
korean
outbreak
result
confirm
mer
case
death
aros
korean
travel
import
merscov
middl
east
august
laboratori
confirm
case
human
infect
death
mortal
current
clinic
manag
serious
ill
mer
patient
fraught
difficulti
merscovspecif
antivir
therapeut
immun
base
treatment
approv
treat
patient
thu
support
care
main
stay
treatment
focus
prevent
complic
particularli
organ
failur
ard
secondari
bacteri
infect
due
high
mortal
hospit
mer
case
empir
treatment
tri
ad
hoc
patient
basi
report
empir
individu
combin
use
steroid
interferon
ifna
ifnb
gener
antivir
drug
tri
use
treat
mer
patient
signific
effect
clinic
outcom
control
random
clinic
trial
treatment
intervent
perform
date
use
convalesc
plasma
monoclon
antibodi
mycophenol
acid
option
avail
requir
evalu
control
clinic
trial
sever
antimerscov
drug
develop
date
antimerscov
therapeut
develop
approv
regulatori
author
unaccept
high
mortal
rate
associ
merscov
epidem
potenti
indic
urgent
need
develop
newer
antimerscov
drug
vaccin
altern
treatment
approach
intern
journal
infecti
diseas
u
r
three
year
first
discoveri
jeddah
saudi
arabia
novel
zoonot
pathogen
human
middl
east
respiratori
syndrom
coronaviru
merscov
continu
major
threat
global
health
secur
sporad
commun
acquir
case
mer
continu
report
middl
east
recent
nosocomi
outbreak
hospit
seoul
korea
nation
guard
hospit
riyadh
saudi
arabia
indic
epidem
potenti
merscov
current
effect
antimerscov
antivir
agent
therapeut
mer
associ
high
mortal
rate
hospitalis
patient
larg
proport
mer
patient
die
rang
pulmonari
patholog
rang
pneumonia
adult
respiratori
distress
syndrom
multiorgan
failur
compound
comorbid
reflect
precari
balanc
interact
hostimmun
system
merscov
whilst
wait
new
merscov
specif
drug
therapeut
vaccin
develop
need
advanc
rang
hostdirect
therapi
rang
hdt
avail
includ
commonli
use
drug
good
safeti
profil
could
augment
host
innat
adapt
immun
mechan
merscov
modul
excess
inflamm
reduc
lung
tissu
destruct
discuss
rational
potenti
use
hostdirect
therapi
improv
poor
treatment
outcom
associ
mer
care
design
random
control
trial
need
determin
whether
hdt
could
benefit
patient
mer
recurr
outbreak
merscov
infect
hospit
middl
east
present
uniqu
opportun
conduct
random
clinic
trial
time
come
coordin
global
respons
mer
multidisciplinari
global
merscov
respons
group
requir
take
forward
prioriti
research
agenda
infect
merscov
present
spectrum
clinic
manifest
asymptomat
mild
sever
diseas
progress
multiorgan
failur
death
larg
proport
patient
infect
merscov
either
asymptomat
mild
ill
complet
recoveri
occur
due
effect
innat
acquir
immun
respons
erad
infect
comprehens
immunopathogenesi
studi
conduct
date
protect
deleteri
human
respons
merscov
remain
determin
pneumonia
multiorgan
involv
common
featur
patient
mer
high
mortal
seen
merscov
could
attribut
acut
lung
injuri
develop
acut
respiratori
distress
syndrom
ard
ard
associ
leaki
alveolarcapillari
interfac
pulmonari
oedema
hypoxia
polymorphonuclear
leucocyt
lymphocyt
cell
upregul
proinflammatori
cytokin
gamma
interferon
aberr
immun
respons
result
tissu
damag
deterior
lung
function
sixti
percent
mer
patient
acut
lung
injuri
ard
either
recov
receiv
intens
care
mer
patient
succumb
diseas
larg
major
patient
die
due
infect
merscov
may
form
immunosuppress
due
old
age
comorbid
condit
diabet
chronic
lung
renal
cardiac
liver
diseas
underli
immunosuppress
condit
appear
outcom
mer
patient
may
repres
precari
balanc
hostand
merscovinduc
immun
signal
event
known
whether
mortal
reflect
ineffect
host
respons
merscov
whether
aberr
host
immun
respons
contribut
pathogenesi
poor
prognosi
intervent
could
manipul
hostpathogen
relationship
via
modul
host
respons
merscov
infect
may
help
improv
mortal
rate
patient
mer
instanc
genom
analysi
suggest
immun
signal
modul
may
affect
outcom
adenosin
deaminas
may
prevent
merscov
entri
host
cell
rang
hostdirect
therapi
hdt
potenti
improv
treatment
outcom
sever
lung
infect
gener
principl
use
hdt
augment
antimerscov
protect
immun
mechan
modul
destruct
immunemedi
inflammatori
respons
protect
tissu
inflammatori
damag
rang
hdt
intervent
avail
requir
evalu
treatment
patient
mer
repurpos
commonli
use
drug
excel
safeti
profil
includ
use
lower
cholesterol
diabet
arthriti
antibiot
epilepsi
cancer
modul
autophagi
promot
immun
effector
mechan
antimicrobi
peptid
product
repair
damag
tissu
micronutri
product
immunemodulatori
effect
cellular
therapi
use
mesenchym
stromal
cell
obtain
patient
bone
marrow
reduc
aberr
inflamm
regener
tissu
induc
antimerscov
immun
respons
sever
commonli
avail
product
longstand
safeti
record
readili
avail
requir
evalu
treatment
sever
mer
open
label
clinic
trial
consid
statin
shown
potenti
treatment
influenza
diseas
lung
injuri
induc
autophagi
matur
phagosom
antiinflammatori
effect
peroxisom
proliferatoractiv
receptorg
transform
growth
factorb
nonsteroid
antiinflammatori
drug
indomethacin
ibuprofen
acetylsalicyl
acid
inhibit
cyclooxygenas
reduc
inflamm
tissu
patholog
overt
inflammatori
immun
respons
curb
use
etoposid
patient
sever
influenza
infect
may
part
due
differenti
suscept
treg
regulatoari
tcell
diabet
drug
metformin
increas
mitochondri
ro
product
enhanc
macrophag
autophagi
sever
cancer
drug
gleevac
imatinib
tyrosin
kinas
inhibitor
activ
autophagi
reduc
inflammatori
respons
doxycyclin
potenti
protect
destruct
degrad
tissu
collagen
structur
protein
matrix
metallo
proteinas
mmp
inhibitor
effect
recent
studi
describ
librari
compound
screen
antivir
activ
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
compound
activ
merscov
sarscov
identifi
compound
includ
inhibitor
dopamin
receptor
use
antipsychot
drug
inhibitor
estrogen
receptor
use
cancer
treatment
mesenchym
stromal
cell
msc
deriv
patient
bone
marrow
may
potenti
modul
aberr
immun
respons
antiinflammatori
tissuerepair
effect
sever
viral
bacteri
infect
lung
use
adjunct
therapi
use
msc
deriv
patient
bone
marrow
expand
ex
vivo
reinfus
current
evalu
rang
infecti
noncommunic
diseas
evalu
improv
treatment
outcom
merscov
hospit
case
encourag
lifesav
result
msc
treatment
patient
ard
repurpos
drug
welldefin
safeti
pharmacokinet
profil
individu
evalu
control
clinic
trial
requir
defin
effect
treatment
sever
case
mer
patient
comorbid
treatment
outcom
measur
would
effect
mortal
lung
function
long
term
sequela
immun
respons
resolut
lung
inflamm
tissu
regener
achiev
optim
treatment
sever
variabl
need
explor
trial
agent
includ
patient
age
presenc
comorbid
ill
extent
diseas
time
intervent
care
design
random
control
trial
need
determin
whether
hdt
could
benefit
patient
mer
optim
studi
hdt
trial
mer
could
benefit
experi
manag
lifethreaten
clinic
situat
overt
inflamm
caus
cytokin
storm
context
tcell
base
therapi
malign
diseas
control
highli
activ
tcell
respons
glucocortocosteriod
yet
may
respond
newer
drug
antitnf
reagent
eg
eternacept
mani
fundament
question
regard
mer
epidemiolog
pathogenesi
protect
immun
respons
viral
kinet
optim
treatment
remain
unansw
three
year
first
discoveri
merscov
respons
group
requir
recurr
outbreak
merscov
infect
hospit
present
uniqu
challeng
control
merscov
time
provid
opportun
conduct
random
clinic
trial
answer
prioriti
research
question
time
come
coordin
global
respons
take
forward
import
prioriti
epidemiolog
translat
clinic
basic
scienc
research
forward
establish
clinic
trial
capabl
within
global
consortia
develop
infrastructur
build
local
capac
take
forward
evalu
new
drug
therapeut
vaccin
